In ISR’s recent CRO Benchmarking study, outsourcers of Phase 2/3 clinical development services were asked to identify attributes that have been rising in importance as CRO selection criteria over the past 12 months.
Forty-two percent of respondents indicated their company has formal agreements in place, but there is a notable difference in preferred provider agreement (PPA) use when viewed through the lens of company size.
ISR recently interviewed 15 individuals in Medical Affairs departments at Top 50 pharma companies to understand how they view their responsibilities, the challenges they face, and trends they are seeing in the Medical Affairs space.
In a recent study on the market outlook for commercial bioprocessing, nearly half of respondents currently have marketed biologics to treat autoimmune disorders (47%) and cancer and related conditions (46%).
Half of respondents who outsource cell and/or gene manufacturing activities to CDMOs are outsourcing process development to ensure the ability to scale-up manufacturing should the therapy advance towards commercialization.
ISR asked respondents responsible for sterile injectable manufacturing outsourcing about the numbers and types of outsourced compounds they have in development and in marketing or foresee themselves having in five years.